TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A November 8 MedPage Today opinion article argues that clinicians and public health agencies should explain how health risks vary across nicotine and tobacco products. The authors say cigarettes remain especially dangerous, nicotine products are not harmless, and evidence is needed on how to communicate relative risks without encouraging new use.
Three researchers in tobacco communication and regulatory science are urging healthcare professionals and public health agencies to explain how risks differ among nicotine and tobacco products, arguing that consumers face conflicting messages as the marketplace expands. In a November 8 opinion article for MedPage Today, Ying Zhang, Andy Tan and Meghan Moran say guidance should distinguish combustible cigarettes from noncombustible products while making clear that no tobacco product is completely safe.
The authors describe a market that includes cigarettes, e-cigarettes, nicotine pouches, smokeless tobacco, snus and heated tobacco products. They say consumers encounter public health warnings, marketing claims and research findings that can appear to point in different directions. The article also notes that some products have received U.S. Food and Drug Administration authorization to carry modified-risk claims.
The authors say the basic advice depends on a person’s current use. People who do not use nicotine or tobacco should not start, they write, citing nicotine’s addictive properties and health risks, including cardiovascular disease. For people who smoke, they identify quitting entirely as the best option and say approved nicotine replacement therapies and prescription medications should generally be considered first-line approaches.
For people unable or not ready to quit, the researchers argue that understanding differences between continued cigarette smoking and using noncombustible products may matter. They say switching completely away from cigarettes can reduce exposure to cigarette smoke, while using cigarettes alongside another nicotine product does not provide the same risk reduction. They caution that this is not an endorsement of vaping, pouches or smokeless tobacco.
Guidance for Smokers and Clinicians
The article addresses a practical communication challenge: people may need to make decisions while facing different products and competing claims. If health professionals describe all products in the same way, the authors argue, smokers may not receive information about how risks differ. But emphasizing relative risk without safeguards could also be misunderstood as approval or as encouragement for people who do not use nicotine to begin.
The authors call for communication that states both sides plainly: combustible cigarettes pose especially high health risks, and nicotine-containing alternatives are not harmless. That distinction matters for clinicians advising patients who smoke, as well as for public health messaging intended to prevent nicotine use among nonusers. The article frames independent, credible communication as a way to help people interpret claims already circulating in advertising and online.
Products Worth Considering
BowFlex Results Series 552 SelectTech Adjustable Dumbbell
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Therabody Theragun Relief Massage Gun, 3-Speed, Black
As an affiliate, we earn on qualifying purchases.
Why Nicotine Messages Conflict
The researchers say the FDA has recognized that combustible products such as cigarettes carry the greatest health risks and that noncombustible products generally fall lower on the risk spectrum. The agency has allowed certain products to be marketed with modified-risk claims stating that using them instead of cigarettes reduces the risk of several serious diseases. That authorization applies to particular products and claims; it does not mean all nicotine products are safe.
The opinion article also points to a paid op-ed about a continuum of product risk, whose byline was attributed to former Health and Human Services Secretary Tom Price. The researchers say a disclosure at the end identified the piece as produced in partnership with and paid for by Philip Morris International. They argue that who funds a message matters, and call for information from sources without a financial stake in selling nicotine products.
““Cigarettes are extraordinarily dangerous, and nicotine is what makes them so hard to quit.””
— Ying Zhang, Andy Tan and Meghan Moran, in their MedPage Today opinion article
How Risk Messages Should Work
The opinion article does not establish which communication method best helps smokers understand relative risks. The authors say possible approaches include patient-provider conversations, public education campaigns or an accessible trusted source, but each could differ in reach, cost and potential unintended effects. They call for research to test which methods inform smokers without encouraging nicotine use among people who otherwise would not start.
The piece is an argument by researchers, not a new clinical guideline or a report of a specific study testing a messaging strategy. It does not supply a comparative risk ranking for every product discussed. Product-specific risks, the effects of long-term use and how people interpret authorized modified-risk claims remain beyond what the article resolves.
Research and Independent Advice
The authors call for evidence on how to communicate product differences clearly and responsibly. They do not announce a study, campaign or policy deadline. Their proposed direction is for clinicians and public health agencies to prepare to answer questions about an expanding range of products, while drawing on credible, independent information and avoiding claims that any nicotine product is risk-free.
For readers, the article’s immediate distinction is between advice not to start, support for smokers seeking to quit, and information about relative risks for people who continue to smoke. The authors say that conversation should not be left solely to product marketing, social media or word of mouth.
Key Questions
What development does the article report?
It is an opinion article published November 8 in MedPage Today. Three researchers argue that clinicians and public health agencies should explain differences in risk across nicotine and tobacco products.
Do the authors say nicotine products are safe?
No. They say no tobacco product is completely safe and warn that nicotine is addictive. Their argument is that risks differ, particularly between combustible cigarettes and noncombustible products.
They say people who do not use nicotine or tobacco should not start. They cite addiction and health risks, including cardiovascular disease.
They argue that understanding relative risks may matter for people who continue to smoke. They say quitting is the best option and that switching completely away from cigarettes differs from using cigarettes alongside another product.
Is there a proven best way to communicate these risks?
No method is established in the article. The authors say more evidence is needed to determine whether clinical conversations, public campaigns or another approach can inform smokers without encouraging new nicotine use.
Source: medpagetoday.com
